# Fructosamine vs. Glycated Hemoglobin in Diabetic Dogs and Cats ## Quick Answer - Fructosamine reflects average blood glucose over the prior 1 to 2 weeks in dogs and cats, while glycated hemoglobin (HbA1c) integrates glycemic control over approximately 2 to 3 months. - For routine diabetic monitoring in dogs and cats, serum fructosamine is the more practical first-line marker because it responds faster to insulin adjustments and requires only a single blood sample. - HbA1c is valuable for longer-term assessment and research settings, but species-specific assay validation and slower response to recent changes limit its routine use in small animal practice. ## Clinical Utility of Fructosamine in Diabetic Dogs and Cats Fructosamine is a glycated serum protein formed by the non-enzymatic binding of glucose to circulating proteins, primarily albumin. Because albumin has a relatively short half-life in dogs and cats, fructosamine concentrations reflect the average blood glucose level over the preceding 1 to 2 weeks. This makes fructosamine a clinically useful marker for assessing glycemic control in diabetic patients during routine recheck examinations. The [American Veterinary Medical Association](https://www.avma.org/resources-tools/pet-owners) emphasizes the importance of regular veterinary care and preventive health monitoring for companion animals, which includes appropriate diagnostic testing for chronic conditions such as diabetes mellitus. Routine measurement of fructosamine fits within this framework of preventive care because it provides objective data on glycemic status that complements owner-reported observations of thirst, urination, appetite, and body weight. For veterinarians managing diabetic dogs and cats, fructosamine offers several practical advantages. A single blood sample can be collected during a routine office visit without requiring hospitalization or serial sampling. The test is widely available through commercial veterinary diagnostic laboratories and can be performed on serum or plasma. Results are typically reported in micromoles per liter, with reference intervals varying by laboratory and assay method. The clinical interpretation of fructosamine requires attention to factors that can influence results. Conditions that alter serum protein concentrations, particularly hypoalbuminemia, can affect fructosamine measurements. Hyperthyroidism in cats can increase protein turnover and lower fructosamine values independent of glycemic status. Conversely, conditions that prolong protein half-life or reduce protein turnover may produce falsely elevated results. Veterinarians should interpret fructosamine in the context of the complete patient profile, including physical examination findings, clinical signs, and serial trends instead of isolated values. A 2024 prospective clinical case series published in [The Veterinary Record](https://pubmed.ncbi.nlm.nih.gov/37608628) examined the relationship between periodontal disease and glycemic control in dogs with diabetes mellitus. The study measured both fructosamine and HbA1c before and after periodontal treatment in ten client-owned dogs with poorly regulated diabetes. The investigators found that HbA1c decreased significantly three months after periodontal treatment, and the severity of periodontal disease at enrollment was positively associated with HbA1c concentration. Fructosamine decreased significantly one month after treatment in dogs with high periodontal disease severity scores but not in dogs with low severity scores. These findings support a potential detrimental interaction between periodontal disease and diabetes management, and they illustrate how both markers respond to changes in inflammatory status and glycemic control over different time frames. ## Glycated Hemoglobin as a Longer-Term Marker Glycated hemoglobin, commonly abbreviated as HbA1c, forms when glucose binds to the hemoglobin molecule within red blood cells. Because red blood cells have a longer lifespan than serum albumin, HbA1c reflects average blood glucose over a longer period. In dogs and cats, the lifespan of red blood cells is approximately 2 to 3 months, which means HbA1c provides an integrated measure of glycemic control over that time frame. The primary advantage of HbA1c is its longer retrospective window. For veterinarians who need to assess whether glycemic control has been stable over several months, HbA1c can provide information that fructosamine cannot. This is particularly relevant when evaluating the effectiveness of long-term management strategies, including insulin dose adjustments, dietary modifications, and treatment of concurrent diseases. However, several limitations affect the routine clinical use of HbA1c in dogs and cats. Assay methods validated for human blood may not perform reliably with canine or feline samples because of species differences in hemoglobin structure and glycation rates. Veterinary diagnostic laboratories may offer species-specific assays, but availability and standardization vary. Additionally, conditions that affect red blood cell lifespan, such as anemia, blood loss, or hemolysis, can alter HbA1c results independent of glycemic status. The 2025 multicenter randomized controlled trial of DWP16001, a sodium-glucose cotransporter 2 inhibitor, in diabetic dogs provides useful comparative data on both markers. The study, published in [BMC Veterinary Research](https://doi.org/10.1186/s12917-025-04962-y), involved 61 dogs receiving stable insulin therapy and measured serum fructosamine at weeks 0, 1, 4, and 8, and HbA1c at weeks 0, 4, and 8. The results showed that DWP16001 significantly reduced both fructosamine and HbA1c concentrations, particularly in dogs with poor baseline glycemic control defined as fructosamine of 500 µmol/L or higher and HbA1c of 6% or higher. The study also detected asymptomatic hypoglycemia in four dogs receiving the drug, which resolved following insulin dose adjustment, and no episodes of diabetic ketoacidosis were recorded. This trial demonstrates that both markers can detect improvements in glycemic control in response to therapeutic interventions. The different sampling schedules for fructosamine and HbA1c in the study protocol reflect their respective retrospective windows, with fructosamine measured more frequently to capture shorter-term changes and HbA1c measured less frequently to assess longer-term trends. ## At a Glance | Feature | Fructosamine | Glycated Hemoglobin (HbA1c) | | --- | --- | --- | | Retrospective window | 1 to 2 weeks | 2 to 3 months | | Sample type | Serum or plasma | Whole blood | | Response to recent insulin changes | Faster | Slower | | Species-specific assay availability | Widely available | Variable | | Effect of protein disorders | Affected by hypoalbuminemia | Affected by anemia or hemolysis | | Typical clinical use | Routine recheck monitoring | Long-term assessment and research | ## Choosing Between Fructosamine and HbA1c in Clinical Practice The selection of a glycemic monitoring marker depends on the clinical question being asked, the patient's status, and the available laboratory resources. For most routine monitoring of diabetic dogs and cats, fructosamine is the preferred initial test because it responds more quickly to changes in insulin therapy and dietary management. A recheck examination typically occurs 1 to 4 weeks after an insulin dose adjustment, and fructosamine can detect meaningful changes within that time frame. HbA1c may be more appropriate when the clinical question concerns long-term stability or when fructosamine results are difficult to interpret because of concurrent disease. For example, a diabetic cat with chronic kidney disease and hypoalbuminemia may have unreliable fructosamine values, making HbA1c a more informative marker. Similarly, when evaluating the overall success of a diabetes management program over several months, HbA1c can provide a summary measure that complements serial fructosamine measurements. The [World Small Animal Veterinary Association](https://wsava.org/global-guidelines) provides global guidelines for companion animal care that emphasize evidence-based approaches to disease management. These guidelines support the use of appropriate diagnostic testing to guide therapeutic decisions and monitor treatment outcomes. The choice between fructosamine and HbA1c should be guided by the same principles, selecting the test that best answers the clinical question while accounting for patient-specific factors and laboratory capabilities. Veterinarians should also consider the practical aspects of sample collection and handling. Fructosamine can be measured on serum or plasma obtained from a routine blood collection, and samples can be shipped to reference laboratories under standard conditions. HbA1c requires whole blood and may have more stringent handling requirements depending on the assay method. Point-of-care analyzers for HbA1c are available but may not be validated for veterinary species, so results should be interpreted with caution unless the laboratory confirms species-specific validation. ## Practical Implementation Steps for Glycemic Monitoring Implementing a structured glycemic monitoring protocol in a veterinary practice requires attention to patient selection, sample collection, result interpretation, and client communication. The following steps provide a framework for integrating fructosamine and HbA1c into diabetic patient management. First, establish a baseline assessment for every newly diagnosed diabetic dog or cat. This should include a complete blood count, serum biochemistry profile, urinalysis, and baseline fructosamine measurement. The baseline fructosamine provides a reference point for future comparisons and helps identify patients with poor glycemic control at diagnosis. The [Merck Veterinary Manual](https://www.merckvetmanual.com/) provides authoritative background on diabetes mellitus diagnosis and management in companion animals, including the role of laboratory testing in establishing baseline status. Second, schedule recheck examinations at appropriate intervals based on the patient's stability. For patients undergoing insulin dose adjustments, a recheck examination with fructosamine measurement is typically recommended 1 to 2 weeks after each dose change. For stable patients, recheck examinations every 1 to 3 months are appropriate, with fructosamine measured at each visit to document ongoing glycemic control. Third, interpret fructosamine results in the context of the complete clinical picture. A single elevated fructosamine value does not necessarily indicate poor control if the patient is clinically stable and owner-reported signs are acceptable. Conversely, a normal fructosamine value in a patient with persistent clinical signs of diabetes warrants investigation for other causes of polyuria, polydipsia, or weight loss. Serial trends are more informative than isolated values, and the direction and magnitude of change should guide therapeutic decisions. Fourth, consider HbA1c measurement when longer-term assessment is needed or when fructosamine interpretation is complicated by concurrent disease. Discuss the availability and validation of species-specific HbA1c assays with the diagnostic laboratory before ordering the test. If HbA1c is measured, interpret results in the context of the patient's red blood cell status and any conditions that might affect red blood cell lifespan. Fifth, document all monitoring results in the medical record and communicate trends to the owner. Clear documentation supports continuity of care and facilitates identification of patterns over time. Owners should understand what each test measures and how results relate to their pet's clinical signs and quality of life. ## Records and Measurements for Diabetic Monitoring Maintaining accurate records is essential for effective diabetic management. The medical record should include the date of each fructosamine or HbA1c measurement, the laboratory used, the assay method, and the result with the laboratory's reference interval. This information allows for accurate comparison of results over time and identification of changes that may warrant therapeutic adjustment. A standardized monitoring log can help track key parameters at each recheck examination. The log should include body weight, body condition score, insulin dose and type, timing of insulin administration relative to meals, owner-reported clinical signs, and any concurrent medications or health conditions. Fructosamine or HbA1c results should be recorded alongside these clinical parameters to facilitate interpretation. The [Cornell University College of Veterinary Medicine](https://www.vet.cornell.edu/) provides educational resources for veterinary professionals and pet owners that emphasize the importance of regular monitoring and documentation in managing chronic diseases. Consistent record keeping supports evidence-based decision making and helps identify trends that might otherwise be missed. When reviewing monitoring records, veterinarians should look for patterns that indicate inadequate glycemic control, such as persistently elevated fructosamine values, progressive weight loss despite adequate food intake, or recurrent episodes of hypoglycemia. These patterns may indicate the need for insulin dose adjustment, dietary modification, or investigation of concurrent disease. ## Common Failure Patterns in Glycemic Monitoring Several common errors can undermine the effectiveness of glycemic monitoring in diabetic dogs and cats. Recognizing these failure patterns can help veterinarians avoid misinterpretation and improve patient outcomes. One common failure is relying on a single fructosamine measurement without considering the clinical context. Fructosamine values can be influenced by factors unrelated to glycemic control, including recent changes in diet, concurrent illness, and medications. A single elevated value should prompt further investigation instead of immediate insulin dose changes, particularly if the patient is clinically stable. Another failure pattern is measuring fructosamine too soon after an insulin dose adjustment. Because fructosamine reflects the preceding 1 to 2 weeks, a measurement taken 2 to 3 days after a dose change will not accurately reflect the effect of the new dose. Veterinarians should wait at least 1 week, and ideally 2 weeks, after a dose adjustment before measuring fructosamine to assess the response. A third failure is using an assay that has not been validated for the species being tested. This is particularly relevant for HbA1c, where human assays may not perform reliably with canine or feline samples. Before ordering HbA1c, veterinarians should confirm that the laboratory uses a species-validated method and provides appropriate reference intervals. A fourth failure is failing to account for conditions that affect the marker being measured. Hypoalbuminemia can lower fructosamine values, while anemia can affect HbA1c results. When these conditions are present, the marker may not accurately reflect glycemic control, and alternative monitoring strategies should be considered. A fifth failure is inadequate client communication about the purpose and limitations of glycemic monitoring. Owners may not understand why blood tests are needed when their pet appears clinically well, or they may misinterpret a single normal fructosamine value as evidence that insulin adjustments are unnecessary. Clear communication about the role of monitoring in preventing complications and maintaining quality of life supports owner compliance and improves outcomes. ## Limitations of Fructosamine and HbA1c in Veterinary Practice Both fructosamine and HbA1c have inherent limitations that veterinarians must recognize when using these tests for diabetic monitoring. Understanding these limitations supports appropriate test selection and interpretation. Fructosamine limitations include dependence on serum protein concentrations, particularly albumin. Conditions that lower albumin, such as protein-losing nephropathy or enteropathy, can produce falsely low fructosamine values. Hyperthyroidism in cats increases protein turnover and can lower fructosamine independent of glycemic status. Conversely, conditions that prolong protein half-life may produce falsely elevated values. Fructosamine also has a relatively short retrospective window, which means it may not detect long-term trends in glycemic control. HbA1c limitations include dependence on red blood cell lifespan and the availability of species-validated assays. Anemia, blood loss, or hemolysis can shorten red blood cell lifespan and lower HbA1c values. Polycythemia or conditions that prolong red blood cell survival can produce falsely elevated values. The longer retrospective window of HbA1c means it responds slowly to recent changes in insulin therapy, making it less useful for monitoring the immediate effects of dose adjustments. The 2024 study of periodontal disease and glycemic control in diabetic dogs illustrates an additional limitation of both markers. The study found that periodontal disease severity was positively associated with HbA1c concentration and that fructosamine decreased after periodontal treatment in dogs with high disease severity scores. These findings suggest that inflammatory conditions can affect glycemic markers through mechanisms independent of insulin therapy, complicating interpretation in patients with concurrent disease. The [World Organisation for Animal Health](https://www.woah.org/en/what-we-do/animal-health-and-welfare) emphasizes the importance of animal health surveillance and welfare in veterinary practice. For diabetic patients, this includes monitoring also glycemic markers but also overall health status, body condition, and quality of life. Glycemic markers are tools to support clinical decision making, not substitutes for comprehensive patient assessment. ## Comparative Performance of Fructosamine and HbA1c in Clinical Studies Clinical studies provide useful comparative data on how fructosamine and HbA1c perform in diabetic dogs under different conditions. The 2025 DWP16001 trial demonstrated that both markers responded to therapeutic intervention, but the study protocol used different sampling intervals for each marker. Fructosamine was measured at weeks 0, 1, 4, and 8, while HbA1c was measured at weeks 0, 4, and 8. This sampling schedule reflects the shorter retrospective window of fructosamine and the longer window of HbA1c. The study also established specific thresholds for defining poor baseline glycemic control. Dogs with fructosamine of 500 µmol/L or higher and HbA1c of 6% or higher were classified as having poor baseline glycemic control. The treatment effect was most pronounced in this subgroup, with significant reductions in both markers. This finding supports the use of both markers to identify patients who may benefit most from additional therapeutic interventions. The 2024 periodontal disease study provided additional comparative data. The investigators measured both markers before and after periodontal treatment in ten dogs with poorly regulated diabetes. HbA1c decreased significantly three months after treatment, while fructosamine decreased significantly one month after treatment in dogs with high periodontal disease severity scores. The different time courses of improvement for the two markers are consistent with their respective retrospective windows. These studies illustrate that fructosamine and HbA1c provide complementary information in clinical settings. Fructosamine detects shorter-term changes in glycemic control, making it useful for monitoring the response to recent therapeutic adjustments. HbA1c detects longer-term trends, making it useful for assessing overall glycemic stability and the impact of interventions that may take several months to exert their full effect. ## Emerging Research on Glycemic Markers and Metabolic Health Recent research has expanded understanding of the relationship between glycemic control and broader metabolic health in diabetic dogs. A 2026 study published in [Animals](https://doi.org/10.3390/ani16060936) used shotgun metagenomic sequencing to examine gut microbiome changes in diabetic dogs compared with healthy controls. The study analyzed fecal samples from 38 diabetic dogs and 37 healthy dogs under controlled conditions with no recent antibiotic or probiotic exposure and stable commercial diets. The investigators found significant separation in gut microbial community structure between diabetic and healthy dogs at both genus and species levels. Diabetic dogs showed enrichment of opportunistic-associated taxa including Enterobacterales and Enterococcus faecalis, while healthy dogs were enriched for putatively beneficial taxa linked to bile acid and short-chain fatty acid metabolism. Functional profiling revealed higher abundances of pathways related to carbohydrate and energy metabolism, membrane transport, and virulence and colonization in diabetic dogs. These findings suggest that diabetes in dogs is associated with a remodeled gut microbiome characterized by expansion of opportunistic pathogens and elevated virulence and metabolic potential. While this research does not directly compare fructosamine and HbA1c, it highlights the importance of comprehensive metabolic assessment in diabetic patients. Glycemic markers provide information about average glucose control, but they do not capture the full spectrum of metabolic disturbances associated with diabetes. The [World Small Animal Veterinary Association](https://wsava.org/global-guidelines) global guidelines support a comprehensive approach to companion animal disease management that extends beyond single laboratory parameters. For diabetic patients, this includes attention to nutrition, body condition, concurrent disease, and overall quality of life in addition to glycemic monitoring. ## Practical Decision Framework for Marker Selection The following decision framework can help veterinarians select the most appropriate glycemic marker for individual patients. The framework considers the clinical question, patient characteristics, and practical constraints. | Clinical Scenario | Recommended Marker | Rationale | | --- | --- | --- | | Routine recheck 1 to 2 weeks after insulin adjustment | Fructosamine | Detects short-term response to dose changes | | Stable patient on long-term management | Fructosamine at each visit | Documents ongoing control and detects drift | | Suspected poor long-term control despite normal fructosamine | HbA1c | Provides longer retrospective window | | Patient with hypoalbuminemia or protein-losing disease | HbA1c | Avoids falsely low fructosamine values | | Patient with anemia or red blood cell disorders | Fructosamine | Avoids falsely low HbA1c values | | Research or clinical trial setting | Both markers | Provides complementary data on glycemic control | For patients with concurrent disease that affects one marker, the alternative marker may provide more reliable information. When both markers are affected by concurrent disease, veterinarians should rely on clinical signs, serial blood glucose measurements, and owner-reported observations to guide management decisions. ## Welfare and Safety Considerations in Diabetic Monitoring Diabetes mellitus management in dogs and cats involves balancing glycemic control against the risk of hypoglycemia. The goal of monitoring is to maintain blood glucose concentrations within an acceptable range while avoiding dangerous fluctuations. Fructosamine and HbA1c provide indirect measures of average glucose but do not detect episodes of hypoglycemia, which can be life-threatening. The [American Animal Hospital Association](https://www.aaha.org/resources) provides practice guidance for companion animal care that emphasizes patient safety and welfare. For diabetic patients, this includes educating owners about the signs of hypoglycemia, such as weakness, lethargy, tremors, and seizures, and providing clear instructions for emergency management. Owners should be advised to contact their veterinarian immediately if they suspect hypoglycemia, and they should have access to emergency veterinary services. The 2025 DWP16001 trial in diabetic dogs reported asymptomatic hypoglycemia in four dogs receiving the drug, which resolved following insulin dose adjustment. This finding underscores the importance of monitoring for hypoglycemia when adjusting diabetes medications and the need for owner education about recognizing and responding to hypoglycemic episodes. Veterinarians should also consider the welfare implications of repeated blood sampling for diabetic monitoring. While blood collection is generally well tolerated in dogs and cats, minimizing the frequency of sampling when clinically appropriate supports patient comfort and owner compliance. Point-of-care testing and careful scheduling of recheck examinations can reduce the burden of monitoring while maintaining adequate surveillance. The [American Veterinary Medical Association](https://www.avma.org/resources-tools/pet-owners) provides resources for pet owners that emphasize the importance of regular veterinary care and preventive health measures. For diabetic pets, this includes regular monitoring appointments, appropriate diagnostic testing, and ongoing communication with the veterinary team. Engaging owners as partners in diabetes management supports better outcomes and improved quality of life for affected animals. ## Professional Escalation Criteria Veterinarians should escalate care or refer to a specialist when glycemic monitoring reveals patterns that suggest inadequate control, complications, or concurrent disease that exceeds the scope of primary care practice. Clear escalation criteria support timely intervention and improve patient outcomes. Immediate escalation is warranted for patients with suspected diabetic ketoacidosis, characterized by vomiting, lethargy, dehydration, and ketonuria. These patients require intensive care, including fluid therapy, insulin administration, and electrolyte management, which may exceed the capabilities of a general practice. The [Merck Veterinary Manual](https://www.merckvetmanual.com/) provides authoritative guidance on the diagnosis and management of diabetic ketoacidosis in companion animals. Urgent escalation is appropriate for patients with recurrent or severe hypoglycemia, particularly if episodes occur despite appropriate insulin dosing and feeding schedules. Recurrent hypoglycemia may indicate excessive insulin doses, inconsistent food intake, or concurrent disease that affects insulin requirements. These patients may benefit from evaluation by a veterinary internal medicine specialist. Routine escalation should be considered when glycemic monitoring indicates persistent poor control despite appropriate insulin therapy and dietary management. Patients with fructosamine values that remain markedly elevated over multiple recheck examinations, or those with progressive weight loss, recurrent infections, or other complications, may benefit from referral for advanced diagnostic testing and management. Veterinarians should also escalate care when monitoring results are difficult to interpret because of concurrent disease. Patients with conditions that affect serum proteins, red blood cells, or metabolic status may require specialized testing or consultation to establish reliable glycemic monitoring. The [World Small Animal Veterinary Association](https://wsava.org/global-guidelines) guidelines support referral to specialists when the complexity of the case exceeds the resources of the primary care practice. ## A Structured Monitoring Protocol for Marker Selection and Interpretation Veterinarians often face the practical challenge of deciding which glycemic marker to use at each recheck examination and how to interpret results when they conflict with clinical observations. A structured monitoring protocol that integrates both fructosamine and HbA1c into a coherent decision pathway can reduce interpretive errors and improve consistency across patients. This section provides a practical framework for marker selection, a record system for tracking longitudinal data, and a troubleshooting method for common interpretive challenges. ### Establishing a Baseline and Defining the Monitoring Interval The first step in any structured monitoring protocol is establishing a reliable baseline for each patient. For a newly diagnosed diabetic dog or cat, the initial assessment should include a complete blood count, serum biochemistry profile, urinalysis, and baseline fructosamine measurement. This baseline serves two purposes. First, it provides a reference point for future comparisons. Second, it helps identify patients with poor glycemic control at diagnosis, defined in the 2025 DWP16001 trial as fructosamine of 500 µmol/L or higher and HbA1c of 6% or higher. These thresholds were used to identify dogs most likely to benefit from additional therapeutic intervention, and they provide a useful starting point for risk stratification in clinical practice. The monitoring interval should be tailored to the patient's stability and the clinical question being addressed. For patients undergoing insulin dose adjustments, fructosamine should be measured 1 to 2 weeks after each dose change. This interval allows the marker to reflect the effect of the new dose because fructosamine integrates glucose over the preceding 1 to 2 weeks. Measuring earlier than 1 week after a dose change will not accurately capture the response and may lead to inappropriate dose adjustments based on incomplete information. For stable patients on long-term management, recheck examinations every 1 to 3 months are appropriate, with fructosamine measured at each visit. The [American Animal Hospital Association](https://www.aaha.org/resources) provides practice guidance that supports regular monitoring for chronic conditions, and this interval aligns with recommended recheck schedules for diabetic patients. HbA1c can be measured at 3-month intervals when longer-term assessment is needed, such as when evaluating the overall success of a management program or when fructosamine interpretation is complicated by concurrent disease. ### A Decision Framework for Marker Selection at Each Recheck The choice between fructosamine and HbA1c at each recheck examination should be guided by the clinical question, patient characteristics, and the time elapsed since the last therapeutic change. The following framework provides a structured approach to marker selection. For routine recheck examinations 1 to 2 weeks after an insulin adjustment, fructosamine is the preferred marker. Its shorter retrospective window allows detection of meaningful changes within this time frame, and it requires only a single serum or plasma sample that can be collected during a routine office visit. The [American Veterinary Medical Association](https://www.avma.org/resources-tools/pet-owners) emphasizes the importance of regular veterinary care for companion animals, and fructosamine measurement fits within this framework by providing objective data that complements owner-reported observations. For stable patients on long-term management, fructosamine should be measured at each recheck to document ongoing control and detect gradual drift. Serial fructosamine measurements are more informative than isolated values because the direction and magnitude of change guide therapeutic decisions. A trend of progressively increasing fructosamine values, even within the reference interval, may indicate the need for insulin dose adjustment or investigation of concurrent disease. HbA1c should be considered when the clinical question concerns long-term stability or when fructosamine results are difficult to interpret because of concurrent disease. For example, a diabetic cat with chronic kidney disease and hypoalbuminemia may have unreliable fructosamine values because low albumin reduces the substrate available for glycation. In this situation, HbA1c may provide more reliable information about average glucose control over the preceding 2 to 3 months. Similarly, when evaluating the overall success of a diabetes management program over several months, HbA1c can provide a summary measure that complements serial fructosamine measurements. The [World Small Animal Veterinary Association](https://wsava.org/global-guidelines) global guidelines support evidence-based approaches to companion animal disease management, and the selection of glycemic markers should follow the same principles. The test chosen should answer the clinical question while accounting for patient-specific factors and laboratory capabilities. ### A Record System for Longitudinal Glycemic Data Effective diabetic management depends on accurate record keeping that allows veterinarians to identify trends over time. A standardized monitoring log should track key parameters at each recheck examination, including body weight, body condition score, insulin dose and type, timing of insulin administration relative to meals, owner-reported clinical signs, and any concurrent medications or health conditions. Fructosamine and HbA1c results should be recorded alongside these clinical parameters to facilitate interpretation. The medical record should include the date of each measurement, the laboratory used, the assay method, and the result with the laboratory's reference interval. This information allows for accurate comparison of results over time and identification of changes that may warrant therapeutic adjustment. Different laboratories may use different assay methods with different reference intervals, so recording the laboratory and assay method is essential for accurate longitudinal comparison. A practical approach to tracking glycemic data is to create a simple spreadsheet or paper log with columns for date, body weight, insulin dose, clinical signs, fructosamine result, HbA1c result, and notes. This format allows veterinarians to scan multiple recheck visits at a glance and identify patterns that might otherwise be missed. For example, a gradual increase in fructosamine over three consecutive recheck examinations, accompanied by stable body weight and no change in owner-reported clinical signs, may indicate the need for insulin dose adjustment even though no single value is markedly elevated. The [Cornell University College of Veterinary Medicine](https://www.vet.cornell.edu/) provides educational resources that emphasize the importance of regular monitoring and documentation in managing chronic diseases. Consistent record keeping supports evidence-based decision making and facilitates communication with owners about their pet's progress. ### Troubleshooting Conflicting Results Veterinarians occasionally encounter situations where fructosamine and HbA1c results conflict with each other or with clinical observations. A structured troubleshooting approach can help identify the cause of the discrepancy and guide appropriate action. When fructosamine and HbA1c results conflict, the first step is to verify the timing of each measurement relative to recent therapeutic changes. Because fructosamine reflects the preceding 1 to 2 weeks and HbA1c reflects the preceding 2 to 3 months, the two markers may legitimately diverge when glycemic control has changed recently. For example, a dog that had poor control 2 months ago but has improved over the past 2 weeks may have a normal fructosamine but an elevated HbA1c. This pattern is expected and does not indicate a laboratory error. Conversely, a dog that had good control 2 months ago but has deteriorated over the past 2 weeks may have an elevated fructosamine but a normal HbA1c. When fructosamine results do not match clinical observations, the next step is to evaluate factors that can affect the marker independent of glycemic status. Hypoalbuminemia can lower fructosamine values, while hyperthyroidism in cats can increase protein turnover and lower fructosamine independent of glycemic control. The 2024 study published in [The Veterinary Record](https://pubmed.ncbi.nlm.nih.gov/37608628) demonstrated that periodontal disease can affect both markers, with periodontal disease severity positively associated with HbA1c concentration and fructosamine decreasing after periodontal treatment in dogs with high disease severity scores. This finding highlights the importance of considering inflammatory conditions when interpreting glycemic markers. When HbA1c results do not match clinical observations, the next step is to evaluate factors that affect red blood cell lifespan. Anemia, blood loss, or hemolysis can shorten red blood cell lifespan and lower HbA1c values, while polycythemia or conditions that prolong red blood cell survival can produce falsely elevated values. Additionally, the availability of species-validated assays should be confirmed with the diagnostic laboratory, because human assays may not perform reliably with canine or feline samples. When both markers conflict with clinical observations, veterinarians should rely on clinical signs, serial blood glucose measurements, and owner-reported observations to guide management decisions. The [Merck Veterinary Manual](https://www.merckvetmanual.com/) provides authoritative background on diabetes mellitus diagnosis and management, including the role of laboratory testing in monitoring. Glycemic markers are tools to support clinical decision making, not substitutes for comprehensive patient assessment. ### Common Failure Patterns in Marker Interpretation Several common errors can undermine the effectiveness of glycemic monitoring. Recognizing these failure patterns can help veterinarians avoid misinterpretation and improve patient outcomes. One common failure is relying on a single fructosamine measurement without considering the clinical context. Fructosamine values can be influenced by factors unrelated to glycemic control, including recent changes in diet, concurrent illness, and medications. A single elevated value should prompt further investigation instead of immediate insulin dose changes, particularly if the patient is clinically stable. Another failure pattern is measuring fructosamine too soon after an insulin dose adjustment. Because fructosamine reflects the preceding 1 to 2 weeks, a measurement taken 2 to 3 days after a dose change will not accurately reflect the effect of the new dose. Veterinarians should wait at least 1 week, and ideally 2 weeks, after a dose adjustment before measuring fructosamine to assess the response. A third failure is using an assay that has not been validated for the species being tested. This is particularly relevant for HbA1c, where human assays may not perform reliably with canine or feline samples. Before ordering HbA1c, veterinarians should confirm that the laboratory uses a species-validated method and provides appropriate reference intervals. A fourth failure is failing to account for conditions that affect the marker being measured. Hypoalbuminemia can lower fructosamine values, while anemia can affect HbA1c results. When these conditions are present, the marker may not accurately reflect glycemic control, and alternative monitoring strategies should be considered. A fifth failure is inadequate client communication about the purpose and limitations of glycemic monitoring. Owners may not understand why blood tests are needed when their pet appears clinically well, or they may misinterpret a single normal fructosamine value as evidence that insulin adjustments are unnecessary. Clear communication about the role of monitoring in preventing complications and maintaining quality of life supports owner compliance and improves outcomes. ### Integrating Glycemic Markers with Broader Metabolic Assessment Recent research has expanded understanding of the relationship between glycemic control and broader metabolic health in diabetic dogs. A 2026 study published in [Animals](https://doi.org/10.3390/ani16060936) used shotgun metagenomic sequencing to examine gut microbiome changes in diabetic dogs compared with healthy controls. The study analyzed fecal samples from 38 diabetic dogs and 37 healthy dogs under controlled conditions with no recent antibiotic or probiotic exposure and stable commercial diets. The investigators found significant separation in gut microbial community structure between diabetic and healthy dogs at both genus and species levels. Diabetic dogs showed enrichment of opportunistic-associated taxa including Enterobacterales and Enterococcus faecalis, while healthy dogs were enriched for putatively beneficial taxa linked to bile acid and short-chain fatty acid metabolism. Functional profiling revealed higher abundances of pathways related to carbohydrate and energy metabolism, membrane transport, and virulence and colonization in diabetic dogs. These findings suggest that diabetes in dogs is associated with a remodeled gut microbiome characterized by expansion of opportunistic pathogens and elevated virulence and metabolic potential. While this research does not directly compare fructosamine and HbA1c, it highlights the importance of comprehensive metabolic assessment in diabetic patients. Glycemic markers provide information about average glucose control, but they do not capture the full spectrum of metabolic disturbances associated with diabetes. The [World Organisation for Animal Health](https://www.woah.org/en/what-we-do/animal-health-and-welfare) emphasizes the importance of animal health surveillance and welfare in veterinary practice. For diabetic patients, this includes monitoring glycemic markers but also overall health status, body condition, and quality of life. Glycemic markers are tools to support clinical decision making, not substitutes for comprehensive patient assessment. ### Practical Implementation Steps for the Monitoring Protocol Implementing a structured glycemic monitoring protocol in a veterinary practice requires attention to patient selection, sample collection, result interpretation, and client communication. The following steps provide a framework for integrating fructosamine and HbA1c into diabetic patient management. First, establish a baseline assessment for every newly diagnosed diabetic dog or cat. This should include a complete blood count, serum biochemistry profile, urinalysis, and baseline fructosamine measurement. The baseline fructosamine provides a reference point for future comparisons and helps identify patients with poor glycemic control at diagnosis. Second, schedule recheck examinations at appropriate intervals based on the patient's stability. For patients undergoing insulin dose adjustments, a recheck examination with fructosamine measurement is typically recommended 1 to 2 weeks after each dose change. For stable patients, recheck examinations every 1 to 3 months are appropriate, with fructosamine measured at each visit to document ongoing glycemic control. Third, interpret fructosamine results in the context of the complete clinical picture. A single elevated fructosamine value does not necessarily indicate poor control if the patient is clinically stable and owner-reported signs are acceptable. Conversely, a normal fructosamine value in a patient with persistent clinical signs of diabetes warrants investigation for other causes of polyuria, polydipsia, or weight loss. Serial trends are more informative than isolated values, and the direction and magnitude of change should guide therapeutic decisions. Fourth, consider HbA1c measurement when longer-term assessment is needed or when fructosamine interpretation is complicated by concurrent disease. Discuss the availability and validation of species-specific HbA1c assays with the diagnostic laboratory before ordering the test. If HbA1c is measured, interpret results in the context of the patient's red blood cell status and any conditions that might affect red blood cell lifespan. Fifth, document all monitoring results in the medical record and communicate trends to the owner. Clear documentation supports continuity of care and facilitates identification of patterns over time. Owners should understand what each test measures and how results relate to their pet's clinical signs and quality of life. ### Professional Escalation Criteria for Monitoring Challenges Veterinarians should escalate care or refer to a specialist when glycemic monitoring reveals patterns that suggest inadequate control, complications, or concurrent disease that exceeds the scope of primary care practice. Clear escalation criteria support timely intervention and improve patient outcomes. Immediate escalation is warranted for patients with suspected diabetic ketoacidosis, characterized by vomiting, lethargy, dehydration, and ketonuria. These patients require intensive care, including fluid therapy, insulin administration, and electrolyte management, which may exceed the capabilities of a general practice. Urgent escalation is appropriate for patients with recurrent or severe hypoglycemia, particularly if episodes occur despite appropriate insulin dosing and feeding schedules. Recurrent hypoglycemia may indicate excessive insulin doses, inconsistent food intake, or concurrent disease that affects insulin requirements. These patients may benefit from evaluation by a veterinary internal medicine specialist. Routine escalation should be considered when glycemic monitoring indicates persistent poor control despite appropriate insulin therapy and dietary management. Patients with fructosamine values that remain markedly elevated over multiple recheck examinations, or those with progressive weight loss, recurrent infections, or other complications, may benefit from referral for advanced diagnostic testing and management. Veterinarians should also escalate care when monitoring results are difficult to interpret because of concurrent disease. Patients with conditions that affect serum proteins, red blood cells, or metabolic status may require specialized testing or consultation to establish reliable glycemic monitoring. The [World Small Animal Veterinary Association](https://wsava.org/global-guidelines) guidelines support referral to specialists when the complexity of the case exceeds the resources of the primary care practice. ## Frequently Asked Questions ### How often should fructosamine be measured in a diabetic dog or cat? Fructosamine is typically measured at each recheck examination, which may occur every 1 to 3 months for stable patients. After an insulin dose adjustment, waiting 1 to 2 weeks before measuring fructosamine allows the marker to reflect the effect of the new dose. ### Can fructosamine be measured at home or does it require a veterinary visit? Fructosamine requires a blood sample and laboratory analysis, so it must be measured through a veterinary clinic or diagnostic laboratory. Home glucose monitoring using a glucometer measures blood glucose directly and provides different information than fructosamine. ### Why might a diabetic pet have a normal fructosamine but still show clinical signs of diabetes? A normal fructosamine indicates acceptable average glucose over the preceding 1 to 2 weeks, but it does not detect episodes of hyperglycemia or hypoglycemia. Clinical signs such as polyuria or polydipsia may occur if blood glucose fluctuates significantly even when the average is acceptable. ### Is HbA1c testing available for dogs and cats at standard veterinary laboratories? Availability varies by laboratory. Some veterinary diagnostic laboratories offer species-validated HbA1c assays, while others may only offer human assays that are not validated for veterinary use. Veterinarians should confirm species validation before ordering HbA1c. ### How does anemia affect HbA1c results in diabetic pets? Anemia shortens red blood cell lifespan or reduces the number of red blood cells available for glycation, which can lower HbA1c values independent of glycemic status. HbA1c results should be interpreted with caution in anemic patients. ### Can fructosamine be used to diagnose diabetes mellitus in dogs and cats? Fructosamine is primarily used to monitor glycemic control in patients already diagnosed with diabetes. Diagnosis of diabetes mellitus is based on persistent hyperglycemia and glucosuria, typically confirmed with a blood glucose measurement and urinalysis. ### What should an owner do if their diabetic pet shows signs of hypoglycemia? Owners should contact their veterinarian immediately if they suspect hypoglycemia. Signs include weakness, lethargy, tremors, and seizures. If the pet is conscious, offering a small amount of honey or syrup may help, but veterinary guidance should be sought without delay. ### How does concurrent illness affect fructosamine results? Concurrent illness can affect fructosamine through changes in serum protein concentrations, protein turnover, or metabolic status. Conditions such as hypoalbuminemia, hyperthyroidism, and inflammatory disease can alter fructosamine independent of glycemic control, so results should be interpreted in the context of the complete patient profile. ## Related Veterinary Guides - [What Is a Titer Test for Dogs and Cats? Should You Use It?](/knowledge/veterinary-medicine/preventive-and-routine-care/what-is-a-titer-test-for-dogs-and-cats-should-you-use-it) - [Monitoring Plans for Animals on Long-Term Corticosteroids](/knowledge/veterinary-medicine/veterinary-pathology-microbiology/monitoring-plans-long-term-corticosteroids-veterinary) - [Monitoring Blood Glucose Curves in Diabetic Dogs and Cats](/knowledge/veterinary-medicine/clinical-pathology/monitoring-blood-glucose-curves-diabetic-dogs-cats) - [Therapeutic Monitoring of Antiepileptic Drugs in Dogs and Cats](/knowledge/veterinary-medicine/veterinary-pathology-microbiology/therapeutic-monitoring-antiepileptic-drugs-dogs-cats) - [Monitoring Serum Lactate in Critically Ill Veterinary Patients](/knowledge/veterinary-medicine/clinical-pathology/monitoring-serum-lactate-critically-ill-veterinary-patients) ## References and Further Reading - [Pet Care](https://www.avma.org/resources-tools/pet-owners). American Veterinary Medical Association. - [AAHA Guidelines](https://www.aaha.org/resources). American Animal Hospital Association. - [Global Guidelines](https://wsava.org/global-guidelines). World Small Animal Veterinary Association. - [Merck Veterinary Manual](https://www.merckvetmanual.com/). Merck Veterinary Manual. - [Cornell University College of Veterinary Medicine](https://www.vet.cornell.edu/). Cornell University. - [Animal Health and Welfare](https://www.woah.org/en/what-we-do/animal-health-and-welfare). World Organisation for Animal Health. - [Preliminary evaluation of the impact of periodontal treatment on markers of glycaemic control in dogs with diabetes mellitus: A prospective, clinical case series.](https://pubmed.ncbi.nlm.nih.gov/37608628). The Veterinary record, 2024. - [Differential glycemic effects of DWP16001 in diabetic dogs according to baseline glycemic status: a multicenter randomized controlled trial.](https://doi.org/10.1186/s12917-025-04962-y). 2025. - [Advantages of Continuous and Non-Invasive Glucose Monitoring in the Geriatric Population: A Systematic Review.](https://doi.org/10.3390/jcm15093194). 2026. - [Cats on dry kibble diet have significantly different microbiome than those on canned wet food.](https://doi.org/10.1038/s44433-025-00001-6). 2026. - [Shotgun Metagenomics Reveals Gut Microbiome Remodeling with Altered Taxonomic Composition and Functional Potential in Diabetic Dogs.](https://doi.org/10.3390/ani16060936). 2026. > This article is educational and is not a substitute for veterinary diagnosis or treatment. Contact a veterinarian for advice about an individual animal.